Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Wang, Hui, Zhang, Yuntao, Huang, Baoying, Deng, Wei, Quan, Yaru, Wang, Wenling, Xu, Wenbo, Zhao, Yuxiu +24 more·2020·Cell
DOI 10.1016/j.cell.2020.06.008

Cited by (749)

Items 301–400 of 749

  1. Development and Evaluation of Recombinant B-Cell Multi-Epitopes of PDHA1 and GAPDH as Subunit Vaccines against Streptococcus iniae Infection in Flounder (Paralichthys olivaceus)
    Xiuzhen Sheng, Honghua Zhang, Min Liu · 2023 · Vaccines
  2. Animal Hosts and Experimental Models of SARS-CoV-2 Infection
    Cristina Parolin, Sara Virtuoso, Marta Giovanetti, Silvia Angeletti, Massimo Ciccozzi, Alessândra Borsetti · 2021 · Chemotherapy
  3. A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
    Chang Ming Guo, Yanan Peng, Lin Lin, Xiaoyan Pan, Mengqi Fang, Yun Zhao, Keyan Bao, Runhan Li, Jian-Bao Han, Jiaorong Chen et al. · 2021 · Cell Reports Medicine
  4. Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19
    V. Botosso, S. Jorge, R. Astray, A. M. de Sá Guimarães, M. Mathor, de Carneiro Patrícia dos Santos, E. Durigon, D. Covas, D. B. D. de Oliveira, Ricardo das Neves Oliveira et al. · 2022 · Scientific Reports
  5. A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca
    Marian S. Boshra, Raghda R. S. Hussein, Marwa Mohsen, Ahmed Abdullah Elberry, Ahmed Essam Altyar, Mahmoud Tammam, Rania M. Sarhan · 2022 · Vaccines
  6. Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD) for COVID-19
    Teodor‐D. Brumeanu, Pooja Vir, Ahmad Faisal Karim, Swagata Kar, Dalia Benetiene, Megan Lok, Jack J. Greenhouse, Tammy Putman-Taylor, Christopher Kitajewski, Kevin K. Chung et al. · 2022 · Human Vaccines & Immunotherapeutics
  7. Oral SARS-CoV-2 Spike Protein Recombinant Yeast Candidate Prompts Specific Antibody and Gut Microbiota Reconstruction in Mice
    Lilin Zhang, Lan Yao, Yanyu Guo, Xiaoyang Li, Li Ma, Ruiqi Sun, Han Xue-qing, Jing Liu, Jinhai Huang · 2022 · Frontiers in Microbiology
  8. Single-nucleus transcriptomic profiling of multiple organs in a rhesus macaque model of SARS-CoV-2 infection
    Qiang Ma, 中国科学院生物物理研究所脑与认知科学国家重点实验室, 北京100101, 中国, Wenji Ma, Tian‐Zhang Song, Zhaobo Wu, Zeyuan Liu, Zhenxiang Hu, Jian-Bao Han, Ling Xu, Bo Zeng et al. · 2022 · 动物学研究
  9. A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice
    Nagisa Tokunoh, Shigeyuki Tamiya, Masato Watanabe, Toru Okamoto, Jessica Anindita, Hiroki Tanaka, Chikako Ono, Toshiro Hirai, Hidetaka Akita, Yoshiharu Matsuura et al. · 2023 · Frontiers in Immunology
  10. COVID-19 Vaccines: Where Did We Stand at the End of 2023?
    Kenneth H. Lundstrom · 2024 · Viruses
  11. The orientation of CpG conjugation on aluminum oxyhydroxide nanoparticles determines the immunostimulatory effects of combination adjuvants
    Zhihui Liang, Hang Bao, Zhiying Yao, Min Li, Chen Chen, Lei Zhang, Huiyang Wang, Yiyang Guo, Yubin Ma, Xuecheng Yang et al. · 2024 · Biomaterials
  12. Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses
    Engin Berber, Ted M. Ross · 2024 · Vaccines
  13. SARS-CoV-2 virus: Vaccines in development
    Qing-Rui Huang, Jing-Hua Yan · 2021 · Fundamental Research
  14. Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology
    Qing Bao, Tao Yang, Mingying Yang, Chuanbin Mao · 2022 · Open Research (University of Surrey)
  15. Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
    Yongliang Feng, Jing Chen, Tian Yao, Yue Chang, Xiaoqing Li, Rongqin Xing, Hong Li, Ruixue Xie, Xiaohong Zhang, Zhiyun Wei et al. · 2021 · Infectious Diseases of Poverty
  16. SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders
    Shubhra Khare, Niharika Niharika, Ajey Singh, Imtiyaz Hussain, N. B. Singh, Subhash C. Singh · 2022 · Applied Biochemistry and Biotechnology
  17. Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions
    Yong Qiu, Chunheng Mo, Lu Chen, Wanlin Ye, Guo Chen, Tao Zhu · 2024 · MedComm
  18. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus
    Jacob A. Dillard, Sharon Taft-Benz, Audrey C. Knight, Elizabeth J. Anderson, Katia D. Pressey, Breantié Parotti, Sabian A. Martinez, Jennifer Diaz, Sanjay Sarkar, Emily A. Madden et al. · 2024 · Nature Communications
  19. Vaccine and vaccination as a part of human life: In view of COVID‐19
    Kizhakkepurakkal Balachandran Megha, Seema A. Nayar, P.V. Mohanan · 2021 · Biotechnology Journal
  20. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19
    Hong Zhou, Wei‐Jian Ni, Wei Huang, Zhen Wang, Ming Cai, Yan-Cai Sun · 2022 · Frontiers in Immunology
  21. A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an AAV hACE2 Mouse Model and non-human primates
    Farshad Guirakhoo, Lucy Kuo, James Peng, Juin-Hua Huang, Be-Shen Kuo, Feng Lin, Yaw-Jen Liu, Zhi Liu, Grace Wu, Shuang Ding et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  22. Viruses as biomaterials
    Tao Yang, Yingfan Chen, Yajing Xu, Xiangyu Liu, Mingying Yang, Chuanbin Mao · 2023 · Materials Science and Engineering R Reports
  23. A Comparative Study of Immunogenicity, Antibody Persistence, and Safety of Three Different COVID-19 Boosters between Individuals with Comorbidities and the Normal Population
    Fatemeh Ashrafian, Fahimeh Bagheri Amiri, Anahita Bavand · 2023 · Vaccines
  24. Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development
    Z. Francis, S. Incerti, Sara A. Zein, Nathanael Lampe, Carlos A. Guzmán, Marco Durante · 2021 · Radiation Research
  25. Carbon-based nanomaterials for viral infection management
    Jinming Yu, Chaiyaporn Kuwentrai, Jian‐Dong Huang · 2021 · Biomicrofluidics
  26. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
    Sicong Yu, Keda Chen, Lei Fang, Haiyan Mao, Xiuyu Lou, Chaonan Li, Yanjun Zhang · 2021 · Vaccines
  27. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants
    Yuntao Zhang, Xiaotong Zheng, Wang Sheng, Hongyang Liang, Yuxiu Zhao, Xiujuan Zhu, Rong Yang, Yadan Zhang, Xiaofei Dong, Weidong Li et al. · 2022 · Vaccines
  28. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches
    K. Watashi · 2020 · Biochemical and Biophysical Research Communications - BBRC
  29. Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
    Jianyang Liu, Qunying Mao, Xing Wu, Qian He, Lianlian Bian, Yu Bai, Zhongfang Wang, Qian Wang, Jialu Zhang, Zhenglun Liang et al. · 2022 · Frontiers in Immunology
  30. Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury
    Marwa Muhammad Abu-Serie, Noha H. Habashy · 2022 · International Journal of Biological Macromolecules
  31. A vaccine delivery system promotes strong immune responses against SARS‐CoV‐2 variants
    Zhiwei Lei, Leqing Zhu, Pan Pan, Zhihui Ruan, Yu Gu, Xichun Xia, Shengli Wang, Weiwei Ge, Yangrong Yao, Fazeng Luo et al. · 2023 · Journal of Medical Virology
  32. Profiles of Cough and Associated Risk Factors in Nonhospitalized Individuals With SARS-CoV-2 Omicron Variant Infection: Cross-Sectional Online Survey in China
    Tingting Xu, Yuehan Chen, Wenzhi Zhan, Kian Fan Chung, Zhongmin Qiu, Kewu Huang, Ruchong Chen, Jiaxing Xie, Gang Wang, Min Zhang et al. · 2024 · JMIR Public Health and Surveillance
  33. Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms
    Chang Ming Guo, Xin Chai, Maidaiti Baerlike, Yingping Liu, Yao Wang, Fei Shao, Qingrui Huang, Weiguo Zhang, Shan Cen, Yijie Dong et al. · 2024 · hLife
  34. Frontrunners in the race to develop a SARS-CoV-2 vaccine
    Raquel Russell, Peter Pelka, Brian L. Mark · 2020 · Canadian Journal of Microbiology
  35. Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
    Appavu K. Sundaram, Daniel F. Ewing, Zhaodong Liang et al. · 2021 · Pathogens
  36. A Brief Overview of COVID-19 Vaccines
    Dariush D Farhud, Shaghayegh Zokaei · 2021 · Iranian Journal of Public Health
  37. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models
    Dandan Li, Ning Luan, Jing Li, Heng Zhao, Ying Zhang, Runxiang Long, Guorun Jiang, Shengtao Fan, Xingli Xu, Han Cao et al. · 2021 · Emerging Microbes & Infections
  38. An Evaluation of Different Types of Peptone as Partial Substitutes for Animal-derived Serum in Vero Cell Culture
    Chloé Lezin, Philippe Mauduit, Georges Uzan · 2022 · Alternatives to Laboratory Animals
  39. The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants
    Jing Pu, Xiaoyang He, Wei Xu, Cong Wang, Qiaoshuai Lan, Chen Hua, Kai Wang, Lu Lu, Shibo Jiang · 2022 · Viruses
  40. Anxiety and fear related to coronavirus disease 2019 assessment in the Spanish population: A cross-sectional study
    Regina Allande‐Cussó, Marta Linares Manrique, Juan Camilo Gómez-Salgado, Adolfo Romero Ruiz, Macarena Romero‐Martín, Juan Jesús García‐Iglesias, Carlos Ruíz-Frutos · 2021 · Science Progress
  41. Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant
    Kevin Paul, Freya Sibbertsen, Daniela Weiskopf, Marc Lütgehetmann, Madalena Barroso, Marta K. Danecka, Laura Glau, Laura Hecher, Katharina Hermann, Aloisa Kohl et al. · 2022 · Frontiers in Immunology
  42. Comparison of Physical and Biochemical Characterizations of SARS-CoV-2 Inactivated by Different Treatments
    Shouzhi Yu, Yangyang Wei, Hongyang Liang, Wenheng Ji, Zhen Chang, Siman Xie, Yichuan Wang, Wanli Li, Yingwei Liu, Hao Wu et al. · 2022 · Viruses
  43. Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine
    Qian Chen, Pei Du, Yuxuan Han, Xuehui Ma, Rong Zhang, Xiaoyu Rong, Xu Zhao, Renyi Ma, Huiting Yang, Anqi Zheng et al. · 2023 · Biosafety and Health
  44. Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
    Behrokh Farahmand, Mona Sadat Larijani, Fatemeh Fotouhi, Alireza Biglari, Rahim Sorouri, Fahimeh Bagheri Amiri, Ali Eslamifar, Tahmineh Jalali, ‪Mostafa Salehi-Vaziri, Mohammad Banifazl et al. · 2023 · Heliyon
  45. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine
    Xingdong Zhou, Hui Wang, Qun Ji, Mingjuan Du, Yuexia Liang, Huanhuan Li, Fan Li, Hang Shang, Xiujuan Zhu, Wei Wang et al. · 2021 · Protein & Cell
  46. A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice
    Shengxue Luo, Panli Zhang, Peng Zou, Cong Wang, Bochao Liu, Cuiling Wu, Tingting Li, Ling Zhang, Yuming Zhang, Chengyao Li · 2021 · Virologica Sinica
  47. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates
    Nawal Ahmed Mohamed Al Kaabi, Abderrahim Oulhaj, Farida Ismail Al Hosani, Shamma K. Al Mazrouei, Omar Najim, Salah Eldin Hussein, Jehad Saleh Abdalla, Mohammed Saifuddin Fasihuddin, Afnan Hassan, Gehad E. ElGhazali et al. · 2022 · Scientific Reports
  48. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
    Masoud Etemadifar, Amir Parsa Abhari, Hosein Nouri, Amirhossein Akhavan-Sigari, Seyed Mohammad Piran Daliyeh, Mohammad Reza Maracy, Mehri Salari, Shiva Maleki, Nahad Sedaghat · 2022 · Human Vaccines & Immunotherapeutics
  49. Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination
    Metodija Sekulovski, Niya Boykova Mileva, Georgi Vasilev, Dimitrina Miteva, Milena Gulinac, Monika Peshevska-Sekulovska, Lyubomir Chervenkov, Hristiana Batselova, Georgi Vasilev, L Tomov et al. · 2023 · Biomedicines
  50. Uveitis after COVID-19 Vaccination
    Je Hyung Hwang · 2022 · Case Reports in Ophthalmology
  51. SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage
    Ruoke Wang, Qi Zhang, Jiwan Ge, Wenlin Ren, Rui Zhang, Jun Lan, Bin Ju, Bin Su, Fengting Yu, Peng Chen et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  52. Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic
    Anna Yu. Popova, A. A. Tarasenko, V. Yu. Smolensky, Svetlana Alexandrovna Egorova, В. С. Смирнов, Ala M Dashkevich, Т.Н. Светогор, Irina N. Glinskaya, Angela L. Skuranovich, Angelica Marsovna Milichkina et al. · 2021 · Russian Journal of Infection and Immunity
  53. A quantitative RT‐qLAMP for the detection of SARS‐CoV ‐2 and human gene in clinical application
    Yejiong Yu, Johnny X. Y. Zhou, Binbin Li, Mengmeng Ji, Yun Wang, Emma Carnaby, Monique Ingrid Andersson, Wei E. Huang, Zhanfeng Cui · 2022 · Microbial Biotechnology
  54. Efficacy and limitations of repurposed drugs and vaccines for COVID-19
    Nensina Murmu, Mrinmoy Sarkar, Sananda Dey, Rahul Manna, Shreya Roy, Tanushree Mondal, Soma Halder, Nandini Bhattacharjee, Sandeep Kumar Dash, Biplab Giri · 2023 · Journal of Medicine Surgery and Public Health
  55. Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
    Altijana Hromić‐Jahjefendić, Kenneth H. Lundstrom, Muhamed Adilović, Alaa A. A. Aljabali, Murtaza M. Tambuwala, Ángel Serrano‐Aroca, Vladimir Nikolaevich Uversky · 2023 · Autoimmunity Reviews
  56. Comparative Review of the State of the Art in Research on the Porcine Epidemic Diarrhea Virus and SARS-CoV-2, Scope of Knowledge between Coronaviruses
    Nora Hilda Rosas-Murrieta, Alan Rodríguez-Enríquez, Irma Herrera Camacho, Lourdes Millán-Pérez-Peña, Gerardo Santos‐López, José Francisco Rivera-Benítez · 2024 · Viruses
  57. Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19
    Natalie M. Kirk, Yu-Ying Liang, H. Ly · 2024 · Virulence
  58. SARS-CoV-2 vaccine development and how Brazil is contributing
    Alex Issamu Kanno, Mayra Mara Ferrari Barbosa, Luana Moraes, Luciana C. C. Leite · 2021 · Genetics and Molecular Biology
  59. Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection
    Yu Fu, Fang Chen, Lifen Cui, Yue Zhao, Henan Zhang, Shuang Fu, Jihong Zhang · 2021 · Vaccines
  60. A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2
    Philipp A. Ilinykh, Sivakumar Periasamy, Kai Huang, Natalia A. Kuzmina, Palaniappan Ramanathan, Michelle N. Meyer, Chad E. Mire, Ivan V. Kuzmin, Preeti Bharaj, Jessica R. Endsley et al. · 2022 · npj Vaccines
  61. Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
    Changrui Lu, Yuntao Zhang, Xiaohu Liu, Fujun Hou, Rujie Cai, Zhibin Yu, Fei Liu, Guohuan Yang, Jun Ding, Jiang Xu et al. · 2023 · Antiviral Research
  62. Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms
    Maryam Bayat, Yahya Asemani, Sajad Najafi · 2021 · International Immunopharmacology
  63. The first Chinese national standards for SARS-CoV-2 neutralizing antibody
    Lidong Guan, Yuanling Yu, Xiaohong Wu, Jianhui Nie, Jun Zhang, Zejun Wang, Na Li, Rui Shi, Hui John Zhao, Hongbo Chen et al. · 2021 · Vaccine
  64. Vaccines for Covid‐19: An insight on their effectiveness and adverse effects
    Naila Qamar, Gul Rukh, Sadiq Noor Khan · 2022 · Journal of Medical Virology
  65. SARS‐CoV‐2 replicating in nonprimate mammalian cells probably have critical advantages for COVID‐19 vaccines due to anti‐Gal antibodies: A minireview and proposals
    Chen, Ji‐Ming · 2021 · Journal of Medical Virology
  66. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
  67. Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines
    Can Yue, Pengyan Wang, Jinmin Tian, George F. Gao, Kefang Liu, William J. Liu · 2023 · International Journal of Biological Sciences
  68. Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID‐19
    Jiansheng Huang, Hui Huang, Dongdong Wang · 2020 · Clinical and Translational Medicine
  69. Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
    Yuntao Zhang, Wenjie Tan, Zhiyong Lou, Baoying Huang, Weimin Zhou, Yuxiu Zhao, Jin Zhang, Hongyang Liang, Na Li, Xiujuan Zhu et al. · 2022 · Vaccines
  70. Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
    Yuntao Zhang, Wenjie Tan, Zhiyong Lou, Yuxiu Zhao, Jin Zhang, Hongyang Liang, Na Li, Xiujuan Zhu, Ling Ding, Baoying Huang et al. · 2022 · Vaccines
  71. Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
    Ainur S. Nurpeisova, Berik M. Khairullin, Ruslan Abitayev et al. · 2022 · Human Vaccines & Immunotherapeutics
  72. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults
    Qinjin Wang, Jie Ning, Ying Chen, Bin Li, Liang Shi, Taojun He, Fang Zhang, Xingchi Chen, Aixia Zhai, Chao Wu · 2022 · Frontiers in Microbiology
  73. COVID-19 vaccines and a perspective on Africa
    Alberto Mantovani, María Rescigno, Guido Forni, Francesca Tognon, Giovanni Putoto, Jerry Ictho, Peter Lochoro · 2023 · Trends in Immunology
  74. Ferrets: A powerful model of SARS-CoV-2
    Yan Mei Zhao, 河北医科大学病原生物学教研室，河北 石家庄 050017，中国, Chang-Le Wang, Zhiyun Gao, Hongxiu Qiao, Weijie Wang, Xinyan Liu, Xia Chuai, 河北医科大学医学与健康研究所，河北 石家庄 050017，中国, 河北省胸科医院肿瘤科，河北 石家庄 050010，中国 · 2023 · 动物学研究
  75. Circular RNAs as emerging regulators in COVID-19 pathogenesis and progression
    Xiaojun Gao, Dan Fang, Yulong Liang, Xin Deng, Chen Ni, Min De ZENG, Mao Luo · 2022 · Frontiers in Immunology
  76. Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19
    Jingli Du, Yue Su, Ruilan Wang, Enjun Dong, Yan Cao, Wenjuan Zhao, Wenping Gong · 2023 · Frontiers in Immunology
  77. Effects of BBIBP-CorV vaccine on gut microbiota and short-chain fatty acids in mice exposed to bis (2-ethylhexyl) phthalate and dioctyl terephthalate
    Miaomiao Teng, Jiaqi Sun, Lihui Zhao, Yunxia Li, Zixuan Zhang, Wentao Zhu, Yuntao Zhang, Fangjingwei Xu, Sixi Xing, Xiaoli Zhao et al. · 2024 · Environment International
  78. Vaccines for Respiratory Viruses—COVID and Beyond
    Kalpana Rajanala, Arun Upadhyay · 2024 · Vaccines
  79. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
    Vikram Srivastava, Ling Niu, Kruttika S. Phadke, Bryan H. Bellaire, Michael W. Cho · 2021 · Frontiers in Immunology
  80. Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines
    Andrea Picchianti Diamanti, Maria Manuela Rosado, Emanuele Nicastri, Giorgio Sesti, Claudio Pioli, Bruno Laganà · 2021 · Frontiers in Immunology
  81. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2
    Sally Mahmoud, Subhashini Ganesan, Nawal Ahmed Mohamed Al Kaabi, S V Naik, Santosh Elavalli, Prem Gopinath, Alaa Mousa Ali, Lara Bazzi, katherine Warren, Walid Abbas Zaher et al. · 2022 · Journal of Clinical Virology
  82. COVID-19: Vaccines and therapeutics
    P. Swapna, Naga Venkata Suryanarayana Birudukota, Ahmed Kamal · 2022 · Bioorganic & Medicinal Chemistry Letters
  83. Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination
    Jie Jiao, Yang Shen, Pan Wang · 2022 · Frontiers in Bioscience-Landmark
  84. Challenges and Recent Advancements in COVID-19 Vaccines
    Shao-Cheng Wang, Chung-I Rai, Yuan‐Chuan Chen · 2023 · Microorganisms
  85. The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality
    Yadira Lobaina, Rong Chen, Edith Suzarte, Panchao Ai, Vivian Huerta, Alexis Musacchio, Ricardo Silva, Changyuan Tan, Alejandro M. Martin, Laura Lazo et al. · 2024 · Viruses
  86. Designing a Novel Nano-Vaccine against SARS-CoV-2
    Ang Gao, Hui Liang, Qi Shen · 2020 · Nano Biomedicine and Engineering
  87. A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2
    Kannan Damodharan, Gandarvakottai Senthilkumar Arumugam, S Ganesan, Mukesh Doble, Sathiah Thennarasu · 2021 · RSC Advances
  88. Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
    Syed Mohammed Basheeruddin Asdaq, Shahamah Jomah, Syed Imam Rabbani, Ali Musharraf Alamri, Salman Khalaf Salem Alshammari, Badr Sami Duwaidi, Majed Al-Shammari, Abdulhakeem S. Alamri, Walaa Fahad Alsanie, Majid Alhomrani et al. · 2022 · Canadian Journal of Infectious Diseases and Medical Microbiology
  89. Rare-earth ions as antibacterial agents for woven wool fabric
    Shota Akioka, Shinji Hirai, Kenta Iijima · 2022 · Chemical Papers
  90. Genomic-transcriptomic analysis identifies the Syrian hamster as a superior animal model for human diseases
    Chuchu Wang, Zhenguo Cheng, Jinxin Miao, Xia Xue, Yunshu Dong, Li Zhao, Haoran Guo, Jianyao Wang, Zhizhong Wang, Shuangshuang Lu et al. · 2025 · BMC Genomics
  91. Post‐COVID‐19 Vaccination (or Long Vax) Syndrome: Putative Manifestation, Pathophysiology, and Therapeutic Options
    Shin Jie Yong, Tiff‐Annie Kenny, Alice Halim, Bala Munipalli, Yousef N. Alhashem, Hajir AlSaihati, Maha F. Al‐Subaie, Nawal Ahmed Mohamed Al Kaabi, Mona A. Al Fares, Mohammed Ahmed Garout et al. · 2025 · Reviews in Medical Virology
  92. SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response.
    Hadida Yasmin, Sudipta Saha, M. Butt, R. Modi, A. J. George, U. Kishore · 2021 · Advances in Experimental Medicine and Biology
  93. Review on Approved and Inprogress COVID-19 Vaccines
    Amir Farnudiyan‐Habibi, Mobina Mirjani, Vahideh Montazeri, Shima Aliebrahimi, Iman Katouzian, Saeed Abdolhosseini, Ali Rahmani, Hossein Keyvani, Seyed Nasser Ostad, Mazda Rad‐Malekshahi · 2022 · Iranian journal of pharmaceutical research
  94. Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats
    Reynaldo Oliva-Hernández, Mildrey Fariñas-Medina, Tamara Hernández-Salazar et al. · 2022 · Toxicology
  95. Animal models for studying coronavirus infections and developing antiviral agents and vaccines
    Qisheng Lin, Chunni Lu, Yuqi Hong, Runfeng Li, Jinding Chen, Weisan Chen, Jianxin Chen · 2022 · Antiviral Research
  96. Nonhuman primate models for evaluation of SARS-CoV-2 vaccines
    Jessica Anne Neil, Maryanne Griffith, Dale Ian Godfrey, Damian F. J. Purcell, Georgia Deliyannis, David Charles Jackson, Steve Rockman, Kanta Subbarao, Terry M. Nolan · 2022 · Expert Review of Vaccines
  97. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19
    Vipul Kumar, Sahil Kumar, Prabodh Chander Sharma · 2022 · International Immunopharmacology
  98. Long-read assembly of major histocompatibility complex and killer cell immunoglobulin-like receptor genome regions in cynomolgus macaque
    Qingxiu Hu, Xiaoqi Huang, Yabin Jin, Rui Zhang, Aimin Zhao, Yiping Wang, Chenyun Zhou, Weixin Liu, Xunwei Liu, Chunhua Li et al. · 2022 · Biology Direct
  99. Lower limb lymphedema and cellulitis as a complication of COVID ‐19 vaccine: A case report
    Ahmad Hosseinzadeh, Kamyar Y. Ebrahimi, Reza Shahriarirad · 2022 · Clinical Case Reports
  100. An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
    Anna Offersgaard, Carlos Rene Duarte Hernandez, Shan Feng, Pavel Marichal‐Gallardo, Kenn Holmbeck, Anne Finne Pihl, Carlota Fernandez-Antunez, Garazi Peña Alzua, Katrine Top Hartmann, Long V. Pham et al. · 2023 · iScience